6.57
+0.46(+7.53%)
Currency In USD
| Previous Close | 6.11 |
| Open | 6.08 |
| Day High | 6.62 |
| Day Low | 6.08 |
| 52-Week High | 7.77 |
| 52-Week Low | 2.6 |
| Volume | 138,310 |
| Average Volume | 145,688 |
| Market Cap | 374.15M |
| PE | -5.87 |
| EPS | -1.12 |
| Moving Average 50 Days | 5.2 |
| Moving Average 200 Days | 4.62 |
| Change | 0.46 |
If you invested $1000 in Design Therapeutics, Inc. (DSGN) since IPO date, it would be worth $193.18 as of September 29, 2025 at a share price of $6.57. Whereas If you bought $1000 worth of Design Therapeutics, Inc. (DSGN) shares 3 years ago, it would be worth $391.3 as of September 29, 2025 at a share price of $6.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Design Therapeutics Appoints Justin Gover to Board of Directors
GlobeNewswire Inc.
Sep 10, 2025 8:01 PM GMT
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veter
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate i
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
GlobeNewswire Inc.
Jun 04, 2025 11:00 AM GMT
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IN